Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems.
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths in 2022. The majority (80%) of lung cancer cases belong to the non-small cell lung carcinoma (NSCLC) subtype. Despite the increased screening efforts, the median five-year survival of metastatic NSCLC remains...
| Publicado en: | Current Oncology Vol. 30; no. 1; pp. 704 - 720 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jan2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=161434278&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 161434278 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Jan2023 vid: 30 iid: 1 pid: 97109 pub: MDPI artinfo: ui: 161434278 10.3390/curroncol30010055 161434278 ppf: 704 ppct: 16 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems. aug: au: Doumat, George Daher, Darine Zerdan, Morgan Bou Nasra, Nasri Bahmad, Hisham F. Recine, Monica Poppiti, Robert affil: Faculty of Medicine, American University of Beirut, Beirut 1107-2020, Lebanon sug: ab: Lung cancer is the second most common cancer and the leading cause of cancer-related deaths in 2022. The majority (80%) of lung cancer cases belong to the non-small cell lung carcinoma (NSCLC) subtype. Despite the increased screening efforts, the median five-year survival of metastatic NSCLC remains low at approximately 3%. Common treatment approaches for NSCLC include surgery, multimodal chemotherapy, and concurrent radio and chemotherapy. NSCLC exhibits high rates of resistance to treatment, driven by its heterogeneity and the plasticity of cancer stem cells (CSCs). Drug repurposing offers a faster and cheaper way to develop new antineoplastic purposes for existing drugs, to help overcome therapy resistance. The decrease in time and funds needed stems from the availability of the pharmacokinetic and pharmacodynamic profiles of the Food and Drug Administration (FDA)-approved drugs to be repurposed. This review provides a synopsis of the drug-repurposing approaches and mechanisms of action of potential candidate drugs used in treating NSCLC, including but not limited to antihypertensives, anti-hyperlipidemics, anti-inflammatory drugs, anti-diabetics, and anti-microbials. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|